NCT03580785 Primary Failure of Eruption (PFE) : Highlighting of Clinical, Radiological and Genetic Diagnostic Criteria: Consequences on the Therapeutic Management
| NCT ID | NCT03580785 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Primary Failure of Eruption |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2018-10-22 |
| Primary Completion | 2025-10-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2018-10-22 with a primary completion date of 2025-10-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary purpose of the study is to identify clinical, radiological and genetic diagnostic criteria for Primary Failure of Eruption (PFE). The secondary purposes are to highlight the genotype-phenotype correlations in the PTHR1 and non-PTHR1 forms and analyze the therapeutic failures.
Eligibility Criteria
Inclusion criteria: * people over 6 years old * people with Primary Failure Eruption Exclusion criteria: * children under 6 years old * endocrine pathology that may interfere with dental eruption * rickets * chemotherapy / radiotherapy * bisphosphonate treatment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03580785 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, studying Primary Failure of Eruption. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03580785 currently recruiting?
Yes, NCT03580785 is actively recruiting participants. Contact the research team at marion.strub@chru-strasbourg.fr for enrollment information.
Where is the NCT03580785 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT03580785 clinical trial?
NCT03580785 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 50 participants.